Over the past two decades, the development of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies has revolutionized the management of newly diagnosed multiple myeloma (NDMM), extending the survival of patients with NDMM significantly both in clinical trials and real-world practice [5,6,7,8,9]. The gene discussed is CD38; the disease is AL amyloidosis.